...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Cancer Treatment Reviews >Patient-reported outcomes after cytotoxic chemotherapy in metastatic castration-resistant prostate cancer: a systematic review.
【24h】

Patient-reported outcomes after cytotoxic chemotherapy in metastatic castration-resistant prostate cancer: a systematic review.

机译：转移性去势抵抗性前列腺癌细胞毒性化疗后患者报告的结果：系统评价。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND: In the clinical setting of metastatic castration-resistant prostate cancer the aim of treatment is palliation. Palliation can refer to symptom management or non-curative treatments. Patient-reported outcome is any outcome based on data provided by patients. The aim of this paper is to perform a systematic review of clinical trials including a patient-reported outcome assessment in patients treated with cytotoxic chemotherapy, and to compare their results by traditional medical and patient-reported outcomes assessment. METHODS: In November 2009 a literature search for published studies was undertaken. Selected phase-3 studies were primarily evaluated on the quality of patient-reported outcomes reporting and assessment methodology. FINDINGS: Health-related quality of life assessment was the most common endpoint, pain control the second one. Results of patient-reported and traditional endpoints analysis are resumed, as well as methodology assessment and quality of patient-reported outcomes reporting. Frequently, methodologic limitations affect patient-reported outcomes assessment in clinical trials, either data analysis, particularly not reporting individual scores of health-related quality of life questionnaires, statistical corrections, limited efforts to avoid missing data, or lacking report of duration of palliative response. CONCLUSIONS: Results of trials can differ if different outcomes, medical or patient-reported, are considered in the analysis. Cytotoxic chemotherapy of metastatic castration-resistant prostate cancer is a challenging issue. A survival benefit is reported only for docetaxel, but this treatment is not always feasible. In all patients, initiation of chemotherapy should be based on patient's preferences within discussion of individual risk and benefit, particularly in patients with extensive asymptomatic and symptomatic metastases.
机译：背景：在转移性去势抵抗性前列腺癌的临床环境中，治疗的目标是缓解。姑息治疗可以指症状治疗或非治愈性治疗。患者报告的结局是基于患者提供的数据的任何结局。本文的目的是对包括细胞毒性化学疗法的患者进行的患者报告的结局评估进行临床试验的系统评价，并通过传统医学和患者报告的结局评估来比较其结果。方法：2009年11月进行了文献检索以寻找已发表的研究。所选的3期研究主要根据患者报告的结局报告和评估方法的质量进行评估。结果：与健康相关的生活质量评估是最常见的终点，第二是疼痛控制。恢复患者报告和传统终点分析的结果，以及方法学评估和患者报告结果报告的质量。方法学上的局限性经常会影响临床试验中患者报告的结局评估，包括数据分析，尤其是未报告与健康相关的生活质量问卷的个人评分，统计更正，避免遗漏数据的有限努力或缺乏姑息反应持续时间的报告。结论：如果在分析中考虑不同的结果（医学或患者报告的），则试验结果可能会有所不同。转移性去势抵抗性前列腺癌的细胞毒性化疗是一个具有挑战性的问题。据报道仅对多西紫杉醇具有生存益处，但是这种治疗并不总是可行的。在所有患者中，化疗的开始应基于患者对个体风险和获益的讨论中的喜好，尤其是在具有广泛无症状和症状转移的患者中。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号